Exosome-derived CDNF Inhibits Astrocyte and T Cell Activation by Regulating HSPA5 and Promotes Repair and Regeneration after Peripheral Nerve Injury

分享:

简介:

论文中使用的产品/服务

询价

摘要

Objective
Peripheral nerve injury (PNI) often triggers a detrimental neuroinflammatory response involving astrocytes and T-cells, hindering functional recovery. This study aimed to investigate the mechanism by which Cerebral Dopamine Neurotrophic Factor (CDNF) modulates astrocyte and T-cell activation and to evaluate its therapeutic potential for promoting nerve regeneration.

Methods
Exosomes (Exo) were engineered to carry CDNF by isolating them from bone marrow mesenchymal stem cells (BMSCs) overexpressing CDNF. The effects of CDNF on the activation of cultured astrocytes and CD8+ T-cells were assessed in vitro by measuring cytokine release, cell proliferation, and activation markers using ELISA, EdU assays, flow cytometry, and Western blotting. Co-immunoprecipitation was employed to investigate the interaction between CDNF and Heat Shock Protein A5 (HSPA5). The therapeutic efficacy of exosome-delivered CDNF (Exo-CDNF) was evaluated in vivo using a rat model of chronic constriction injury (CCI), a model for PNI-induced neuropathic pain.

Results
CDNF suppressed the activation of astrocytes and CD8+ T-cells, as evidenced by reduced production of pro-inflammatory cytokines (TNF-α, IL-1β), decreased cell proliferation, and attenuated NF-κB pathway activation. Exo-CDNF was effectively internalized by astrocytes and T-cells, exerting similar inhibitory effects. Mechanistically, we discovered a direct interaction between CDNF and HSPA5. Overexpression of HSPA5 counteracted the immunosuppressive effects of CDNF. In vivo, systemic administration of Exo-CDNF alleviated neuropathic pain behaviors, reduced spinal cord apoptosis and neuroinflammation, and improved histological outcomes in CCI rats.

Conclusion
Our findings demonstrate that Exo-mediated delivery of CDNF effectively suppresses astrocyte and T-cell activation by regulating HSPA5. This study reveals a novel immunomodulatory role for the CDNF-HSPA5 axis and highlights Exo-CDNF as a promising therapeutic strategy for promoting repair and regeneration following peripheral nerve injury.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*